In addition, both failure-free survival and overall survival were significantly longer following BCNU treatment in patients with brain tumours that expressed low to intermediate levels of AGAT (<60 000 molecules per nucleus) compared to those with tumours expressing high levels of AGAT (progression-free survival, 6 vs 3 months (P=0.008); overall survival, 29 vs 8 months (P<0.0002)) (Jaeckle et al, 1998). The gene discussed is GATM; the disease is brain neoplasm.